Journal article
An open label pilot trial of low-dose lithium for young people at ultra-high risk for psychosis
SM Rice, B Nelson, GP Amminger, SM Francey, LJ Phillips, MB Simmons, M Ross, HP Yuen, AR Yung, K O'Gorman, PD McGorry, SJ Wood, GE Berger
Early Intervention in Psychiatry | WILEY | Published : 2024
DOI: 10.1111/eip.13526
Abstract
Aim: Lithium, even at low doses, appears to offer neuroprotection against a wide variety of insults. In this controlled pilot, we examined the safety (i.e., side-effect profile) of lithium in a sample of young people identified at ultra-high risk (UHR) for psychosis. The secondary aim was to explore whether lithium provided a signal of clinical efficacy in reducing transition to psychosis compared with treatment as usual (TAU). Methods: Young people attending the PACE clinic at Orygen, Melbourne, were prescribed a fixed dose (450 mg) of lithium (n = 25) or received TAU (n = 78). The primary outcome examined side-effects, with transition to psychosis, functioning and measures of psychopatholo..
View full abstractRelated Projects (2)
Grants
Awarded by University of Melbourne
Funding Acknowledgements
The authors gratefully acknlowedge the contributions of Husseini K. Manji and Christos Pantelis. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.